← FDA DRUG APPROVALS

FDA ANDA · ANDA075428

GABAPENTIN

Sponsor: SANDOZ

APPLICATION
ANDA075428
TYPE
ANDA
ORIGINAL APPROVAL
2006-01-24
LATEST ACTION
2026-07-16
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

GABAPENTINDiscontinued
GABAPENTIN 400MG · CAPSULE · ORAL
GABAPENTINDiscontinued
GABAPENTIN 100MG · CAPSULE · ORAL
GABAPENTINDiscontinued
GABAPENTIN 300MG · CAPSULE · ORAL

Approval history

2026-07-16Labeling · Supplement 7 · standardAP
2024-12-16Labeling · Supplement 6 · standardAP
2024-07-08Labeling · Supplement 4 · standardAP
2024-07-08Labeling · Supplement 5 · standardAP
2006-01-24OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →